查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018714

醫藥契約製造與研發服務市場：2026-2032年全球市場預測（依服務類型、分子類型、劑型、治療領域及顧客類型分類）

Pharmaceutical Contract Manufacturing & Research Services Market by Service Type, Molecule Type, Dosage Form, Therapeutic Area, Customer Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，醫藥契約製造和研發服務市場價值將達到 2,148.7 億美元，到 2026 年將成長至 2,372 億美元，到 2032 年將達到 4,440.3 億美元，複合年成長率為 10.92%。

主要市場統計數據
基準年 2025 2148.7億美元
預計年份：2026年 2372億美元
預測年份 2032 4440.3億美元
複合年成長率 (%) 10.92%

一份策略性產業指南，旨在協調研究重點、製造能力和監管合規性，以加速產品開發並降低商業化風險。

在技​​術創新、監管日益複雜以及戰略採購體系重組等多重壓力下，醫藥契約製造和研發服務的格局正在改變。本文重點闡述了領導者最關注的關鍵問題：如何在加快臨床試驗速度的同時，確保生產品質和合規性。策略團隊必須制定協調一致的藍圖，將早期研究決策與後期生產和商業化路徑銜接起來，而不是僅僅追求漸進式改善。

科學的複雜性、數位轉型和夥伴關係的重新定義如何重塑整個產業的能力、合約模式和競爭差異化。

生物製藥領域正經歷著由科學複雜性、數位化和重新定義的夥伴關係模式所驅動的變革。生物製藥和先進治療方法正在推動對專業設施和特定領域專業知識的投資，從而催生了對擴充性、靈活的生產平台的需求。同時，數位化品質系統、即時分析和預測性維護的採用正在改變營運預期，並提升契約製造的資產利用率。

我們評估不斷變化的關稅趨勢如何促使企業做出策略採購、供應商多元化和在地化生產決策，以確保供應的連續性。

美國關稅政策已成為供應鏈規劃、籌資策略和服務交付成本計算的關鍵變數。近期關稅調整的累積影響促使企業重新評估供應商選址、原料採購和庫存佈局，更重視供應鏈的韌性而非短期成本套利。因此，企業正在權衡集中式低成本採購與跨國分散式供應鏈（以降低關稅波動風險）之間的利弊。

詳細的細分洞察，將每種服務類型的特徵和最終用戶的優先順序與供應商選擇標準、合約設計和營運風險緩解措施連結起來。

根據服務類型和最終用戶的不同，細分市場的特定趨勢決定了投資、能力和策略重點的分配方向。基於服務類型，企業可以利用諮詢服務，專注於品質保證和法規諮詢，以應對複雜的核准流程，並使內部流程與外部合作夥伴的能力相符。在生產服務方面，原料藥生產、生技藥品生產和製劑生產需要差異化評估。製劑需求進一步細分為液體製劑、半固態製劑和固態製劑，每種製劑都需要獨特的製程管制和包裝的考量。研究服務涵蓋生物分析服務、臨床研究服務、藥物發現、臨床前研究和毒性測試，每個環節都對資料完整性、樣本處理和分析驗證有特定的要求。

在全球主要地區，地理採購選擇如何影響研發和製造專案的監管策略、生產力計畫和韌性優先事項？

區域趨勢持續影響採購選擇、監管策略和產能投資，並以特定方式影響供應韌性和專業能力的取得。在美洲，強大的臨床試驗能力和成熟的法規環境支持著快速研發項目和一體化研發產量模式，而供應商網路仍集中在規模優勢和完善品質系統的特定中心。同時，在歐洲、中東和非洲（EMEA）地區，管理體制和卓越研究中心較為分散，迫使企業在獲取先進生技藥品專業知識與應對多司法管轄區核准和物流相關的行政複雜性之間尋求平衡。

深入了解供應商差異化和合作夥伴選擇，並專注於整合能力、數位品質系統和已驗證的技術轉移記錄。

如今，供應商必須展現其在研發、監管和生產等各個環節的跨職能能力，因此，企業的能力和策略定位比以往任何時候都更加重要。主要企業透過整合服務組合、投資數位化品質體係以及在技術轉移和監管溝通方面的卓越業績來脫穎而出。這些供應商也在投資培養能夠連接科學開發和程式工程的人才，從而實現從實驗到商業化生產的平穩過渡。同時，專注於特定領域的專家則吸引了那些需要專業問題解決方案而非廣泛生產能力的客戶，他們提供特定領域的深厚專業知識，並為新型生物製藥和複雜製劑提供客製化的開發支援。

為加速內部管治結構重組、供應商多元化以及做好數位化和監管合規準備，提出切實可行的跨職能建議，以確保專案穩健執行。

行業領導企業應採取一系列切實可行的措施，使其內部結構與外部供應商的能力以及不斷變化的地緣政治現實相匹配。首先，他們應組成跨職能團隊，涵蓋採購、研發、法規事務和品質保證等部門，從統一的觀點評估供應商機會，兼顧科學需求和營運實際情況。其次，他們應優先考慮與那些能夠快速技術轉移、具備多地點生產能力以及擁有可記錄的監管合作經驗的供應商建立合作關係，以縮短實施時間並降低檢查風險。第三，他們應投資建立內部數位化品管和資料完整性系統，以促進整合並實現對外包活動的即時監控。

採用透明的多來源調查方法，結合專家訪談、監管審查和情境分析，來檢驗策略和營運影響。

本分析的研究途徑結合了對行業趨勢的跨學科審查、對各領域專家的定性訪談，以及對公開監管指南和企業資訊披露的系統整合。主要資訊來源包括與製造業企業領導者、監管事務專家和研發主管的討論，以檢驗觀察到的趨勢，並從多個角度分析其對採購、設施投資和產能發展的影響。二級資訊來源包括科學文獻、監管指南文件和企業技術手冊，以確保觀察結果基於檢驗的實踐和政策。

結論是透過策略夥伴關係、能力投資和積極主動的供應鏈韌性措施，將複雜性轉化為優勢。

總之，受治療方法日益複雜、數位化進步以及貿易格局變化等因素驅動，醫藥契約製造與研發服務生態系統正處於策略轉捩點。認知到研發決策、供應商能力和監管準備之間相互依存關係的機構，將更有利於在保證品質和合規性的同時加速研發進程。為實現此目標，領導者必須超越單純的交易型採購模式，採用包含責任共用、一體化規劃和能力透明化的夥伴關係模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：醫藥契約製造與研發服務市場：依服務類型分類

  • 原料藥生產
  • 製藥生產
  • 包裝和整理
  • 發展服務
  • 臨床試驗服務
  • 檢驗和測試服務
    • 品管和出貨檢驗
    • 穩定性測試
    • 生物分析和微生物檢測

第9章：按分子類型分類的製藥契約製造與研發服務市場

  • 低分子化合物
  • 生物製藥
  • 先進治療方法

第10章：以劑型分類的藥品契約製造與研發服務市場

  • 口服固態劑型
  • 口服液
  • 吸入/鼻噴劑
  • 眼藥水

第11章：醫藥契約製造與研發服務市場：依治療領域分類

  • 腫瘤學
  • 循環系統/新陳代謝
  • 中樞神經系統
  • 感染疾病
  • 免疫學/炎症
  • 呼吸系統
  • 消化系統和肝臟
  • 皮膚科
  • 眼科
  • 罕見疾病/孤兒

第12章：醫藥契約製造與研發服務市場：依客戶類型分類

  • 大型製藥企業
  • 中型製藥公司
  • 新興虛擬製藥公司
  • 生物技術
  • 學名藥生產商
  • 非處方藥生產商
  • 消費者健康營養保健品公司
  • 學術機構和非營利組織

第13章：醫藥契約製造與研發服務市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：醫藥契約製造與研發服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：藥品契約製造與研發服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國製藥契約製造與研發服務市場

第17章：中國醫藥契約製造與研發服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Almac Group
  • Amanta Healthcare Ltd.
  • Aragen Life Sciences Ltd.
  • Automatic Liquid Packaging Solutions LLC
  • Baxter Pharmaceutical Solutions LLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc
  • Curida AS
  • Dalton Pharma Services
  • Evonik Industries AG
  • Famar Group
  • Horizon Pharmaceuticals, Inc
  • Laboratorios SALVAT, SA
  • Lonza Group Ltd.
  • Nephron Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recipharm AB
  • Rommelag SE & Co. KG
  • Rusoma Laboratories Private Limited
  • Silgan Unicep
  • Unither Pharmaceuticals SAS
  • UPM Pharmaceuticals, Inc.
  • Woodstock Sterile Solutions
Product Code: MRR-AD36CD898497

The Pharmaceutical Contract Manufacturing & Research Services Market was valued at USD 214.87 billion in 2025 and is projected to grow to USD 237.20 billion in 2026, with a CAGR of 10.92%, reaching USD 444.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 214.87 billion
Estimated Year [2026] USD 237.20 billion
Forecast Year [2032] USD 444.03 billion
CAGR (%) 10.92%

A strategic industry primer that aligns research priorities, manufacturing capability, and regulatory readiness to accelerate development and de-risk commercialization

The pharmaceutical contract manufacturing and research services landscape is evolving under the simultaneous pressures of technological innovation, regulatory complexity, and strategic sourcing realignments. This introduction frames the single most important consideration for leaders: the need to reconcile speed to clinic with manufacturing quality and regulatory robustness. Strategic teams must move beyond incremental improvements and adopt coordinated road maps that link early research decisions with late-stage manufacturing and commercialization pathways.

Across the continuum, organizations face converging disruptions. Advanced biologics platforms raise the bar for facility design and workforce competency, while digitalization of quality systems promises efficiency gains but requires disciplined change management. As a result, partnerships with external service providers are shifting from transaction-based engagements to outcome-driven collaborations. This change influences internal governance, supplier scorecards, and the structure of commercial agreements.

Consequently, executives should treat contract manufacturing and research services as integral components of product strategy rather than outsourced line items. By aligning procurement, R&D, and regulatory affairs early, companies can reduce downstream surprises and accelerate program delivery. The remainder of this executive summary builds on that premise, offering insight into strategic shifts, tariff-related headwinds, segmentation-specific implications, regional differentiators, and pragmatic recommendations for leaders ready to act.

How scientific complexity, digital transformation, and partnership redefinition are reshaping capabilities, contracting, and competitive differentiation across the industry

The sector is undergoing transformative shifts driven by scientific complexity, digital enablement, and redefined partnership models. Biotherapeutics and advanced modalities have prompted investments in specialized facilities and niche expertise, which in turn have created demand for scalable, flexible manufacturing platforms. Meanwhile, the adoption of digital quality systems, real-time analytics, and predictive maintenance is changing operational expectations and enabling higher asset utilization across contract manufacturing organizations.

At the same time, life science organizations are rethinking relationships with external suppliers, moving from one-off orders to integrated alliances that encompass joint development, co-investment in capacity, and shared risk models. This transition favors providers with cross-functional capabilities in research, regulatory support, and multiphase manufacturing. Consequently, procurement professionals and R&D leaders are increasingly focused on a provider's ability to deliver end-to-end solutions and to demonstrate regulatory compliance across jurisdictions.

Finally, talent and culture are becoming competitive differentiators. Organizations that successfully combine scientific depth with process engineering expertise and digital fluency will lead. Therefore, stakeholders should prioritize capability audits and partner assessments that evaluate not only technical performance but also adaptability and governance structures. These shifts require companies to update decision frameworks, contracting approaches, and internal competencies to secure reliable, future-proof supply and research pathways.

Assessing how evolving tariff dynamics are prompting strategic sourcing, supplier diversification, and localized manufacturing decisions to safeguard supply continuity

Tariff policy in the United States has emerged as a consequential variable for supply chain planning, procurement strategies, and cost-to-serve calculations. The cumulative effects of recent tariff adjustments have prompted organizations to reassess supplier footprints, raw material sourcing, and inventory positioning in ways that emphasize resilience over short-term cost arbitrage. As a result, firms are evaluating trade-offs between consolidated low-cost sourcing and diversified multi-jurisdictional supply chains that reduce exposure to tariff volatility.

These adjustments have downstream impacts on lead times, supplier qualification cycles, and demand for local manufacturing or tolling arrangements. Companies that previously relied heavily on single-country suppliers now face longer qualification timelines when onboarding alternate providers, creating a strong incentive to engage early with contract manufacturing partners that offer multi-country manufacturing footprints or validated secondary suppliers. Simultaneously, procurement teams are expanding their remit to include trade policy monitoring and tariff scenario planning as routine inputs to supplier negotiations.

Importantly, regulatory compliance and quality standards remain non-negotiable amid tariff-driven reshoring or nearshoring initiatives. Consequently, firms should prioritize partners capable of rapid technology transfer and regulatory dossier updates. In the near term, organizations that integrate tariff risk into sourcing strategies, supplier scorecards, and contingency playbooks will improve continuity of supply and protect development timelines despite ongoing external trade pressures.

Detailed segmentation insights that link service type specificity and end-user priorities to supplier selection criteria, contractual design, and operational risk mitigation

Segment-specific dynamics shape where investments, capabilities, and strategic priorities should land across service types and end-users. Based on service type, organizations are engaging consulting services that focus on quality assurance consulting and regulatory consulting to navigate complex approval pathways and to align internal processes with external partner capabilities. Manufacturing services demand differentiated assessment across API manufacturing, biologics manufacturing, and finished dosage form manufacturing, with finished dosage form needs further divided into liquid formulations, semi-solid formulations, and solid formulations, each requiring distinct process controls and packaging considerations. Research services span bioanalytical services, clinical research services, drug discovery, preclinical research, and toxicology studies, and each node in that chain imposes specific data integrity, sample handling, and analytical validation requirements.

Based on end-user, stakeholders include academic and government research institutes that prioritize translational capabilities and reproducibility; biotechnology companies that emphasize speed, platform flexibility, and specialized biologics capacity; and pharmaceutical companies that require scale, global regulatory experience, and integrated supply solutions. The intersection of service type and end-user profile drives supplier selection criteria: companies seeking accelerated clinical timelines will favor research providers with deep bioanalytical and clinical trial operations, while mature pharmaceutical firms will assess manufacturing partners for global regulatory track record and high-volume capacity. Therefore, segmentation insight points to the need for tailored contracting frameworks, capability verification protocols, and integrated risk assessments that reflect the unique technical and commercial contours of each service-end-user pairing.

How geographic sourcing choices across major global regions influence regulatory strategy, capacity planning, and resilience priorities for development and manufacturing programs

Regional dynamics continue to influence sourcing choices, regulatory strategy, and capacity investments with distinct implications for supply resilience and access to specialized capabilities. In the Americas, strength in clinical trial capacity and a mature regulatory ecosystem supports rapid development programs and integrated development-manufacturing pathways, while supplier networks remain concentrated in select hubs that offer scale and established quality systems. Conversely, Europe, Middle East & Africa presents a patchwork of regulatory regimes and centers of excellence, where companies must balance access to advanced biologics expertise with the administrative complexity of multi-jurisdictional approvals and logistics.

Across the Asia-Pacific region, manufacturing capacity and skilled process development talent have expanded rapidly, offering cost-efficient production alternatives and specialized biologics experience; however, organizations must carefully evaluate supplier compliance history and data integrity practices. Transitioning between regions requires robust technology transfer protocols, harmonized quality agreements, and a clearly defined plan for regulatory filings and inspection readiness. Taken together, regional insight underscores the importance of aligning geographic sourcing strategies with product modality, regulatory timelines, and corporate resilience objectives to achieve operational continuity and strategic flexibility.

Insights on provider differentiation and partnership selection that emphasize integrated capabilities, digital quality systems, and proven technology transfer track records

Company capabilities and strategic positioning matter more than ever when providers must demonstrate cross-functional delivery across research, regulatory, and manufacturing domains. Leading firms differentiate through integrated service portfolios, investments in digital quality systems, and proven track records in technology transfer and regulatory interactions. These providers also invest in talent that bridges scientific development and process engineering, enabling smoother scale-up from bench to commercial output. Conversely, niche specialists offer deep modality expertise and bespoke development support for novel biologics or complex formulations, attracting clients that require specialized problem-solving rather than broad-scale capacity.

Partnership selection should therefore prioritize demonstrable end-to-end capabilities, transparent quality metrics, and governance mechanisms that support joint accountability. Strategic considerations include a provider's ability to mobilize cross-site resources, to maintain validated supply chains for critical raw materials, and to support regulatory submissions across major jurisdictions. In addition, firms demonstrating robust digitalization roadmaps and real-world evidence capabilities are increasingly valuable for programs that demand agility and data-driven decision making. Ultimately, company-level insight points to the need for rigorous due diligence frameworks that assess operational readiness, financial stability, and cultural fit to ensure long-term program success.

Practical, cross-functional recommendations to realign internal governance, diversify suppliers, and accelerate digital and regulatory readiness for resilient program delivery

Industry leaders should pursue a set of actionable steps that align internal structures with external provider capabilities and evolving geopolitical realities. First, integrate cross-functional teams that include procurement, R&D, regulatory affairs, and quality assurance to evaluate supplier opportunities through a unified lens that balances scientific needs with operational realities. Second, prioritize partnerships with providers that can demonstrate rapid technology transfer, multi-site manufacturing footprints, and documented regulatory interactions to reduce onboarding timelines and inspection risk. Third, invest in digital quality and data integrity systems internally to smooth integrations and to enable real-time oversight of outsourced activities.

Beyond these immediate actions, firms should develop supplier diversification playbooks that account for tariff volatility and logistics disruptions, and they should build scenario-based contingency plans that are exercised regularly. Leadership should also elevate talent strategies that retain critical scientific and process expertise while fostering collaboration skills necessary for effective external partnerships. Finally, allocate resources to targeted audits and joint development pilots that validate capabilities before committing to long-term volume contracts. Taken together, these recommendations enable leaders to convert strategic intent into operational resilience and to sustain competitive advantage amid a changing industry landscape.

Transparent, multi-source research methodology combining expert interviews, regulatory review, and scenario analysis to validate strategic and operational implications

The research approach for this analysis combined a multi-disciplinary review of industry developments, qualitative interviews with subject matter experts, and structured synthesis of publicly available regulatory guidance and corporate disclosures. Primary inputs included discussions with manufacturing leaders, regulatory affairs specialists, and R&D executives to validate observed trends and to triangulate implications for sourcing, facility investment, and capability development. Secondary sources encompassed scientific literature, regulatory agency guidance documents, and company technical briefs to ground observations in verifiable practice and policy.

Analysis prioritized the identification of practical implications rather than quantitative projections, focusing on capability gaps, operational bottlenecks, and governance approaches that affect program timelines and supplier selection. Data integrity, reproducibility, and regulatory readiness were assessed through a combination of expert validation and documentary review. Where applicable, scenario analysis was applied to explore the operational consequences of tariff shifts and supplier concentration, and findings were stress-tested against stakeholder feedback to ensure robustness. This methodology emphasizes transparency and applicability so that recommendations can be adapted to specific organizational contexts and decision priorities.

Concluding perspective on turning complexity into advantage through strategic partnerships, capability investments, and proactive supply chain resilience measures

In closing, the pharmaceutical contract manufacturing and research services ecosystem is at a strategic inflection point driven by modality complexity, digital adoption, and shifting trade dynamics. Organizations that recognize the interdependence of research decisions, supplier capabilities, and regulatory preparedness will be better positioned to accelerate development while preserving quality and compliance. To achieve this, leaders must move beyond transactional sourcing and adopt partnership models that embed shared accountability, integrated planning, and capability transparency.

Moreover, regional nuances and tariff-driven supply chain adjustments require proactive scenario planning and supplier diversification to protect program timelines. Finally, investment in talent, digital quality systems, and rigorous due diligence processes will determine which organizations can successfully translate external partnerships into sustained operational performance. By acting decisively on these imperatives, stakeholders can convert uncertainty into structured opportunity and establish a durable advantage in a rapidly evolving industry.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Contract Manufacturing & Research Services Market, by Service Type

  • 8.1. Drug Substance Manufacturing
  • 8.2. Drug Product Manufacturing
  • 8.3. Packaging & Finishing
  • 8.4. Development Services
  • 8.5. Clinical Trial Services
  • 8.6. Laboratory & Testing Services
    • 8.6.1. Quality Control & Release Testing
    • 8.6.2. Stability Studies
    • 8.6.3. Bioanalytical & Microbiology Testing

9. Pharmaceutical Contract Manufacturing & Research Services Market, by Molecule Type

  • 9.1. Small Molecules
  • 9.2. Biologics
  • 9.3. Advanced Therapies

10. Pharmaceutical Contract Manufacturing & Research Services Market, by Dosage Form

  • 10.1. Oral Solid
  • 10.2. Oral Liquid
  • 10.3. Inhalation & Nasal
  • 10.4. Ophthalmic

11. Pharmaceutical Contract Manufacturing & Research Services Market, by Therapeutic Area

  • 11.1. Oncology
  • 11.2. Cardiovascular & Metabolic
  • 11.3. Central Nervous System
  • 11.4. Infectious Diseases
  • 11.5. Immunology & Inflammation
  • 11.6. Respiratory
  • 11.7. Gastrointestinal & Hepatology
  • 11.8. Dermatology
  • 11.9. Ophthalmology
  • 11.10. Rare Diseases & Orphan

12. Pharmaceutical Contract Manufacturing & Research Services Market, by Customer Type

  • 12.1. Large Pharma
  • 12.2. Mid-Sized Pharma
  • 12.3. Emerging & Virtual Pharma
  • 12.4. Biotech
  • 12.5. Generic Drug Companies
  • 12.6. Over-The-Counter Drug Companies
  • 12.7. Consumer Health & Nutraceutical Companies
  • 12.8. Academic & Non-Profit Sponsors

13. Pharmaceutical Contract Manufacturing & Research Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pharmaceutical Contract Manufacturing & Research Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pharmaceutical Contract Manufacturing & Research Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pharmaceutical Contract Manufacturing & Research Services Market

17. China Pharmaceutical Contract Manufacturing & Research Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Almac Group
  • 18.7. Amanta Healthcare Ltd.
  • 18.8. Aragen Life Sciences Ltd.
  • 18.9. Automatic Liquid Packaging Solutions LLC
  • 18.10. Baxter Pharmaceutical Solutions LLC
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Cambrex Corporation
  • 18.13. Catalent, Inc
  • 18.14. Curida AS
  • 18.15. Dalton Pharma Services
  • 18.16. Evonik Industries AG
  • 18.17. Famar Group
  • 18.18. Horizon Pharmaceuticals, Inc
  • 18.19. Laboratorios SALVAT, S.A
  • 18.20. Lonza Group Ltd.
  • 18.21. Nephron Pharmaceuticals Corporation
  • 18.22. Pfizer, Inc.
  • 18.23. Recipharm AB
  • 18.24. Rommelag SE & Co. KG
  • 18.25. Rusoma Laboratories Private Limited
  • 18.26. Silgan Unicep
  • 18.27. Unither Pharmaceuticals SAS
  • 18.28. UPM Pharmaceuticals, Inc.
  • 18.29. Woodstock Sterile Solutions

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG PRODUCT MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG PRODUCT MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG PRODUCT MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY PACKAGING & FINISHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY PACKAGING & FINISHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY PACKAGING & FINISHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY QUALITY CONTROL & RELEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY QUALITY CONTROL & RELEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY QUALITY CONTROL & RELEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOANALYTICAL & MICROBIOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOANALYTICAL & MICROBIOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOANALYTICAL & MICROBIOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ADVANCED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ADVANCED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INHALATION & NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INHALATION & NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INHALATION & NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CARDIOVASCULAR & METABOLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CARDIOVASCULAR & METABOLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CARDIOVASCULAR & METABOLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GASTROINTESTINAL & HEPATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GASTROINTESTINAL & HEPATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GASTROINTESTINAL & HEPATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RARE DISEASES & ORPHAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RARE DISEASES & ORPHAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RARE DISEASES & ORPHAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MID-SIZED PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MID-SIZED PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MID-SIZED PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY EMERGING & VIRTUAL PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY EMERGING & VIRTUAL PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY EMERGING & VIRTUAL PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GENERIC DRUG COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GENERIC DRUG COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GENERIC DRUG COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OVER-THE-COUNTER DRUG COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OVER-THE-COUNTER DRUG COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OVER-THE-COUNTER DRUG COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CONSUMER HEALTH & NUTRACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CONSUMER HEALTH & NUTRACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CONSUMER HEALTH & NUTRACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ACADEMIC & NON-PROFIT SPONSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ACADEMIC & NON-PROFIT SPONSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ACADEMIC & NON-PROFIT SPONSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 201. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)